HomeCompareDIGP vs PFE

DIGP vs PFE: Dividend Comparison 2026

DIGP yields 19230.77% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DIGP wins by $35559072563224756224.00M in total portfolio value
10 years
DIGP
DIGP
● Live price
19230.77%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35559072563224756224.00M
Annual income
$35,199,015,251,958,400,000,000,000.00
Full DIGP calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DIGP vs PFE

📍 DIGP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDIGPPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DIGP + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DIGP pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DIGP
Annual income on $10K today (after 15% tax)
$1,634,615.38/yr
After 10yr DRIP, annual income (after tax)
$29,919,162,964,164,640,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, DIGP beats the other by $29,919,162,964,164,640,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DIGP + PFE for your $10,000?

DIGP: 50%PFE: 50%
100% PFE50/50100% DIGP
Portfolio after 10yr
$17779536281612378112.00M
Annual income
$17,599,507,625,979,200,000,000,000.00/yr
Blended yield
98.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DIGP
No analyst data
Altman Z
-104.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DIGP buys
0
PFE buys
0
No recent congressional trades found for DIGP or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDIGPPFE
Forward yield19230.77%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$35559072563224756224.00M$51.1K
Annual income after 10y$35,199,015,251,958,400,000,000,000.00$27,210.54
Total dividends collected$35535307211105599488.00M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DIGP vs PFE ($10,000, DRIP)

YearDIGP PortfolioDIGP Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,933,777$1,923,076.92$9,161$701.38+$1.92MDIGP
2$349,620,709$347,551,567.77$8,610$859.79+$349.61MDIGP
3$59,099,530,219$58,725,436,060.68$8,366$1,081.25+$59099.52MDIGP
4$9,340,702,082,592$9,277,465,585,257.05$8,483$1,405.66+$9340702.07MDIGP
5$1,380,374,723,530,610$1,370,380,172,302,236.20$9,084$1,907.24+$1380374723.52MDIGP
6$190,743,943,336,084,320$189,266,942,381,906,560.00$10,418$2,732.78+$190743943336.07MDIGP
7$24,646,546,669,772,927,000$24,442,450,650,403,320,000.00$13,007$4,193.56+$24646546669772.91MDIGP
8$2,978,031,531,272,736,000,000$2,951,659,726,336,079,400,000.00$18,010$7,005.87+$2978031531272736.00MDIGP
9$336,502,160,062,018,500,000,000$333,315,666,323,556,700,000,000.00$28,216$12,979.89+$336502160062018496.00MDIGP
10$35,559,072,563,224,757,000,000,000$35,199,015,251,958,400,000,000,000.00$51,081$27,210.54+$35559072563224756224.00MDIGP

DIGP vs PFE: Complete Analysis 2026

DIGPStock

Digipath, Inc., together with its subsidiaries, provides cannabis and hemp lab testing services in Las Vegas to Nevada licensed medical marijuana enterprises. It also provides testing, cannabis education and training, and cannabis news coverage to the cannabis industry. The company operates as a testing laboratory facility for cannabis, cannabis infused products, hemp, and other botanical nutraceuticals to serve growers, dispensaries, caregivers, producers, patients, and end users of cannabis and botanical products. In addition, its labs screen medicinal and recreational cannabis for potentially harmful contaminants, including residual solvents; moisture; water activity; visual inspection; pesticides; heavy metals, such as mercury, arsenic, lead, cadmium, chromium, and nickel; biological toxins comprising aflatoxin and ocratoxins; and microbial contaminants consisting of E. coli, salmonella, coliforms, aspergillus, gram negative bacteria, total aerobic bacteria, and mold and yeast. Digipath, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

Full DIGP Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DIGP vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DIGP vs SCHDDIGP vs JEPIDIGP vs ODIGP vs KODIGP vs MAINDIGP vs JNJDIGP vs MRKDIGP vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.